The prognostic role of mismatch repair status and CDX-2 expression with inflammatory markers and pathological risk factors in stage ıı and ııı colon cancer: Multicenter real-life data
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2024Yazar
Aydın, Sabin GöktaşÖlmez, Ömer Fatih
Selvi, Oğuzhan
Geredeli, Çağlayan
Özden, Ferhat
Bilici, Ahmet
Açıkgöz, Özgür
Karcı, Ebru
Kutlu, Yasin
Hamdard, Jamshid
Aydın, Ahmet
Üst veri
Tüm öğe kaydını gösterKünye
Aydın, S. G., Ölmez, Ö. F., Selvi, O., Geredeli, Ç., Özden, F., Bilici, A. ... Aydın, A. (2024). The prognostic role of mismatch repair status and CDX-2 expression with inflammatory markers and pathological risk factors in stage ıı and ııı colon cancer: Multicenter real-life data. Journal of Gastrointestinal Cancer, 55(1), 227-236. http://dx.doi.org/10.1007/s12029-023-00953-0Özet
Objective: Colorectal cancer is common worldwide, and adjuvant treatment’s benefit is still controversial. We designed this study to determine the role of MSI and CDX-2 status determined by immunohistochemistry (IHC) combined with the inflammatory markers and pathological parameters in predicting disease recurrence in stage II and III colon cancer. Methods: A total of 226 stage II/III colon cancer patients with a median age of 59 years who underwent initial surgery were included in this retrospective study. The pathologic assessment of MSI and CDX-2 was performed twice by immunohistochemistry (IHC) and two different pathologists. No staining/weak staining below 10% of the tumor was accepted as CDX-2 negative, and any MSI clones with weak staining below 10% were accepted as MSI-H. The laboratory parameters were noted at the initial diagnosis. Results: One hundred twenty-one and 105 patients were diagnosed with stage III and II colon cancer. 58.0% of patients were male, 46 (20.4%) of tumor tissue were MSS, and 17 (7.5%) were CDX-2 negative. One hundred twenty-nine tumors were localized in the right colon. Disease recurrence was significantly correlated with tumor localization, CDX-2 status, stage at diagnosis, and preoperatively median CRP and CEA levels. DFS rates for MSS patients with CDX-2 negative and positive were 36.7% and 98.1%, respectively [p < 0.001]. There was no significant correlation between MSI status and CDX-2 status. MSI status, the presence of adjuvant treatment, and systemic inflammatory markers were not significant prognostic factors for DFS. CDX-2 status [HR:0.08, CI 95% 0.03–0.17, p < 0.001 HR: 1.7, CI 95% 1.1–3.0, p = 0.03], disease stage [HR:2.6, CI 95% 1.43–4.74], and preoperatively CEA levels [HR:4.1 CI 95% 2.18–785, p < 0.001 were independent significant prognostic factors for DFS. Conclusion: CDX-2 loss was an independent prognostic factor for DFS and disease recurrence in early-stage colon cancer. MSS patients with CDX-2 loss had significantly worse survival outcomes, and this might be the reason for deciding on adjuvant chemotherapy.
Scopus Q Kategorisi
Q3Kaynak
Journal of Gastrointestinal CancerCilt
55Sayı
1Koleksiyonlar
- Makale Koleksiyonu [3736]
- PubMed İndeksli Yayınlar Koleksiyonu [4177]
- Scopus İndeksli Yayınlar Koleksiyonu [6494]
- WoS İndeksli Yayınlar Koleksiyonu [6562]